CancerNCT07767448
Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events
A study testing La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream and La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) in people with Cancer, run by Stanford University at 1 site in United States.
Trial summary
The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream and La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2026to Feb 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patient (18 years or older).
- Patients diagnosed with cancer.
- Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and/or immune checkpoint inhibitors).
- Patient experiencing a dermatological adverse event from a cancer treatment or therapy.
Who cannot join
- Patient is unable to understand scope of the study.
- Patient is unable to provide written informed consent.
- Patient is healthy.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Stanford Health Care: Supportive Dermato-Oncology Program
Palo Alto, California, 94304
Hannah Clinical Research Coordinator, 650-487-1218, hannah05@stanford.edu
Lisa Zaba, MD, PhD
About this study
Official title: Characterization of Skin Changes (Clinical, Physiological and Pathological) Leading to Dermatological Adverse Events From Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immune Checkpoint Inhibitors
The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:
Does cosmeceutical topical moisturizers help with skin dryness?
Participants will:
- Visit the clinic for a baseline visit to complete skin evaluation and tests.
- Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.
- Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.
- Conditions
- Cancer
- Being tested
- La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body WashOther
Moisturizer wash applied once in the morning and once in the evening.
La Roche Posay Lipikar AP+ Triple Repair Moisturizing CreamOther
Moisturizer applied once in the morning and once in the evening.
La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)Other
Balm applied once in the morning and once in the evening.
| Study group | Role | What they receive |
|---|---|---|
| Moisturizer | Experimental | Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study:
1. La Roche Posay Lipikar wash Atopy-Prone Plus (AP+) moisturizing face and body wash (once in the morning and once in the evening)
2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening)
3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening) Receives: Other: La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash; Other: La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream; Other: La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Patient-Reported Skin Dryness Severity
Change in patient-reported skin dryness severity from baseline to follow-up visit (2-4 weeks) as measured by validated dryness severity scale (0-10 numerical rating scale where 0 = no dryness and 10 = severe dryness).
Measured: From baseline visit to follow-up visit (approximately 2-4 weeks).
Secondary outcomes (3)
Time to improvement in dryness symptoms
The time from baseline to the first documented improvement in dryness symptoms, defined as either a ≥2-point reduction in dryness severity score from baseline or patient-reported meaningful improvement in dryness symptoms, whichever occurs first. Lower values indicate a faster improvement in symptoms.
Measured: From baseline visit to follow-up visit (2-4 weeks).
Change in Stratum Corneum Hydration
Change in skin hydration from baseline to follow-up, measured using corneometry and reported in corneometry units (CU). Higher corneometry values indicate greater stratum corneum hydration. Positive changes from baseline reflect improved skin hydration, whereas negative changes indicate reduced hydration.
Measured: From baseline visit to follow-up visit (2-4 weeks).
Change in Transepidermal Water Loss (TEWL)
Change in skin barrier function from baseline to follow-up, measured by transepidermal water loss (TEWL) and reported in g/h/m². TEWL quantifies the amount of water that passively evaporates through the skin. Lower TEWL values indicate improved skin barrier integrity and reduced water loss, while higher values indicate increased barrier disruption. Negative changes from baseline reflect improvement, whereas positive changes indicate worsening skin barrier function.
Measured: From baseline visit to follow-up visit (2-4 weeks).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2026
- Study startOct 2026 (estimated)
- Primary completionSep 2028 (estimated)
- Study completionFeb 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Collaborators
- L'Oreal
- Responsible party
- Sponsor
- Investigators
- Lisa Zaba, MD, PhD, Principal investigator, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07767448
- Sponsor's protocol ID
- IRB-86852
- Other IDs
- NCI-2026-06569
- Status last verified
- Sep 2026
- First submitted
- 10 Aug 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Characterization of Skin Changes (Clinical, Physiological and Pathological) Leading to Dermatological Adverse Events From Chemotherapy, Targeted Therapy, Hormonal Therapy, and Immune Checkpoint Inhibitors
- ClinicalTrials.gov ID
- NCT07767448
- Acronym / sponsor ID
- IRB-86852
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- L'Oreal
- Study start
- Oct 2026 (estimated)
- Primary completion
- Sep 2028 (estimated)
- Study completion
- Feb 2029 (estimated)
- First posted
- 17 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is:
Does cosmeceutical topical moisturizers help with skin dryness?
Participants will:
- Visit the clinic for a baseline visit to complete skin evaluation and tests.
- Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit.
- Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Moisturizer | Experimental | Other: La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, Other: La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, Other: La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study: 1. La Roche Posay Lipikar wash Atopy-Prone Plus (AP+) moisturizing face and body wash (once in the morning and once in the evening) 2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening) 3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult patient (18 years or older).
- Patients diagnosed with cancer.
- Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and/or immune checkpoint inhibitors).
- Patient experiencing a dermatological adverse event from a cancer treatment or therapy.
Key exclusion criteria (3 listed)
- Patient is unable to understand scope of the study.
- Patient is unable to provide written informed consent.
- Patient is healthy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body WashMoisturizer wash applied once in the morning and once in the evening. | Other | Moisturizer |
| La Roche Posay Lipikar AP+ Triple Repair Moisturizing CreamMoisturizer applied once in the morning and once in the evening. | Other | Moisturizer |
| La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)Balm applied once in the morning and once in the evening. | Other | Moisturizer |
Primary outcome
Change in Patient-Reported Skin Dryness Severity
Time frame: From baseline visit to follow-up visit (approximately 2-4 weeks).
Change in patient-reported skin dryness severity from baseline to follow-up visit (2-4 weeks) as measured by validated dryness severity scale (0-10 numerical rating scale where 0 = no dryness and 10 = severe dryness).
3 secondary outcomes
Time to improvement in dryness symptoms
Time frame: From baseline visit to follow-up visit (2-4 weeks).
Change in Stratum Corneum Hydration
Time frame: From baseline visit to follow-up visit (2-4 weeks).
Change in Transepidermal Water Loss (TEWL)
Time frame: From baseline visit to follow-up visit (2-4 weeks).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lisa Zaba, MD, PhD principal investigator
Stanford University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing La Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream and La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) in people with Cancer, run by Stanford University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Research Coordinator (650-497-1218, hannah05@stanford.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Patient-Reported Skin Dryness Severity (time frame: From baseline visit to follow-up visit (approximately 2-4 weeks).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.